Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 70 | ECE2020 | Next issue

22nd European Congress of Endocrinology

05 Sep 2020 - 09 Sep 2020

Card image cap
Europe's leading endocrinology congress showcasing the very best in the study and treatment of endocrine disorders.

Oral Communications

Bone and Calcium

ea0070oc2.1 | Bone and Calcium | ECE2020

Real-life clinical study: 1-year of treatment with burosumab of children and adolescents affected with X-linked hypophosphatemia

Zhukouskaya Volha , Mannes Ines , Chaussain Catherine , Audrain Christelle , Lambert Anne-Sophie , Adamsbaum Catherine , Kamenicky Peter , Nevoux Jerome , Wicart Philippe , Briot Karine , Di Rocco Federico , Trabado Séverine , Prié Dominique , Di Somma Carolina , Colao Annamaria , Rothenbuhler Anya , Linglart Agnès

Background/Aim: X-linked hypophosphatemia (XLH) is a rare disease caused by PHEX mutation, leading to elevated FGF23, renal phosphate wasting, hypophosphatemia, insufficient 1,25(OH)2D synthesis. Clinically, it manifests with rickets including leg deformities, poor growth, dental abscesses, craniosynostosis, and hearing loss. Beyond conventional treatment (phosphate supplements + active vitamin D), burosumab is pathogenetic anti-FGF23 therapeutic approa...

ea0070oc2.2 | Bone and Calcium | ECE2020

STOPFOP: A european phase II clinical trial using saracatinib to prevent FOP

Smilde Bernard , Keen Richard , Stockklausner Clemens , Liu Dong , Bullock Alex , Von Delft Annette , Van Schoor Natasja , Yu Paul , Eekhoff Elisabeth

Background: Fibrodysplasia ossificans progressiva (FOP) is a rare, genetic and devastating disease characterized by progressive heterotopic ossifications (HO) in muscles, tendons, ligaments and fascia. The formation of HO leads to severe contractures and early death. There are no approved medications yet. The STOPFOP team identified AZD0530 (saracatinib) as a potent, low nanomolar inhibitor of the mutant ALK2 kinase which is the unique genetic driver of this rare bone disease....

ea0070oc2.3 | Bone and Calcium | ECE2020

Prediction algorithm for persistent primary hyperparathyroidism after parathyroidectomy

Repaci Andrea , Vicennati Valentina , Salituro Nicola , Vandi Giulia , Zavatta Guido , Altieri Paola , Di Dalmazi Guido , Gambineri Alessandra , Pelusi Carla , Burgio Luca , Piccin Ottavio , Cavicchi Ottavio , Pagotto Uberto

Background: Primary hyperparathyroidism (PHPT) is characterized by an excessive secretion of the parathyroid hormone (PTH) with normal or high calcium levels. The gold standard therapy involves minimally invasive parathyroidectomy with intraoperative PTH (ioPTH) monitoring. Different criteria have been identified when predicting cure rates using ioPTH values.Objective: To evaluate the percent ioPTH drop (ΔioPTH), the post-excision ioPTH, the first p...

ea0070oc2.4 | Bone and Calcium | ECE2020

Loss of glucocorticoid rhythm induces an osteoporotic phenotype in mice

Winter Elizabeth M , Schilperoort M , Kroon J , Kooijman S , Mletzko K , Busse B , Pereira AM , Appelman-Dijkstra NM , Bravenboer N , Rensen PCN , Meijer OC

Introduction: Glucocorticoid (GC)-induced osteoporosis is a widespread problem that is accompanied with increased fracture risk. Currently, it is unknown whether detrimental effects of GC therapy on bone are simply the consequence of supraphysiological GC doses, or whether absence of the endogenous GC rhythm also plays a role. In this study, we aimed to elucidate the importance of the presence of a diurnal corticosterone (CORT) rhythm, the primary GC in mice, for bone quality....

ea0070oc2.5 | Bone and Calcium | ECE2020

Effect of nine months of vitamin D supplementation on areal and volumetric bone mass density and bone architecture in graves’ disease: a double-blinded, randomized clinical trial

Grove-Laugesen Diana , Ebbehoj Eva , Watt Torquil , Würgler Hansen Klavs , Rejnmark Lars

Background: Vitamin D is important to skeletal health and is standard care in conditions with low BMD. Thyrotoxicosis caused by Graves’ disease (GD) leads to increased bone turnover and reduced BMD. We aimed to test the hypothesis that vitamin D supplementation would improve bone recovery in GD.Methods: Using a double-blinded design, hyperthyroid patients with a first time diagnosis of GD were randomized to supplementation with vitamin D3 70 mg/day...

ea0070oc2.6 | Bone and Calcium | ECE2020

Superior efficacy of calcifediol soft gelatin capsules vs cholecalciferol independently of bmi, for the management of vitamin d deficiency in postmenopausal women: a treatment to be considered in therapeutic guidelines

Jódar Esteban , Pérez-Castrillón José Luis , Dueñas-Laita Antonio , Hernández Gonzalo , Fernández-Hernando Nieves , Arranz-Gutiérrez Paula

Background: Vitamin D deficiency is a worldwide health issue that affects more than one billion people. Few guidelines assess optimal dosing of vitamin D in general population, and although there is no international consensus, the optimum dosing for vitamin D3 and mainly calcifediol is not known.Objective(s): To assess the efficacy of calcifediol in the treatment of vitamin D deficiency, compared with therapeutic guidelines recommendations for cholecalci...

ea0070oc2.7 | Bone and Calcium | ECE2020

Surgery alone or surgery in combination with postoperative zoledronic acid for the treatment of osteoporosis in primary hyperparathyroidism: a 2-year double-blind randomized placebo-controlled study

Ryhänen Eeva , Koski Anna-Mari , Eliisa Loyttyniemi , Ulla Kiviniemi , Schalin-Jantti Camilla , Matti Välimäki

Background: Osteoporosis is common in primary hyperparathyroidism (PHPT). It is also an indication for parathyroidectomy in PHPT. Bone mineral density (BMD) measured by dual-energy x-ray absorptiometry (DXA) increases after successful surgery. Alendronate significantly increases BMD in PHPT patients not undergoing surgery. It is not known whether surgery alone or in combination with postoperative zoledronic acid more efficiently improves bone health in PHPT.<p class="abste...